Mutations in the metalloprotein Cu,Zn-superoxide dismutase (SOD1) cause approximately 20% of familial cases of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease for which effective therapeutics do not yet exist. Transgenic rodent models based on over-expression of mutant SOD1 have been developed and these have provided opportunity to test new therapeutic strategies and to study the mechanisms of mutant SOD1 toxicity. Although the mechanisms of mutant SOD1 toxicity are yet to be fully elucidated, incorrect or incomplete metallation of SOD1 confers abnormal folding, aggregation and biochemical properties, and improving the metallation state of SOD1 provides a viable therapeutic option. The therapeutic effects of delivering copper (Cu) to mutant SOD1 have been demonstrated recently. The aim of the current study was to determine if delivery of zinc (Zn) to SOD1 was also therapeutic. To investigate this, SOD1G37R mice were treated with the metal complex diacetyl-bis(4-methylthiosemicarbazonato)zinc II [Zn 
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that involves the loss of functional motor neurons in the spinal cord resulting in progressive paralysis and death within 3-5 years of diagnosis (Pratt et al., 2012) . Incomplete understanding of the pathogenesis of ALS has contributed to the absence of effective therapeutics for the disease: Riluzole is currently the only approved drug for the treatment of ALS but its efficacy is marginal with only a modest extension in survival (Bensimon et al., 1994; Miller et al., 1996) . Pre-clinical development of new treatment options is needed, not only to identify compounds with potential for successful clinical translation, but also to advance our understanding of ALS pathogenesis.
The majority of ALS cases arise sporadically with no known cause. However, 10% of cases are familial (Pratt et al., 2012) and of those, approximately 20% are due to mutations in the gene for Cu,Zn superoxide dismutase (SOD1) (Andersen et al., 2003) , a ubiquitous enzyme responsible for scavenging superoxide radicals (Perry et al., 2010) . Transgenic rodent models that over-express mutant forms of SOD1 develop ALS like symptoms and despite legitimate caveats associated with all transgenic over-expression animal models of human disease, these mutant SOD1 animals remain the current gold-standard for pre-clinical development of new ALS therapeutics (Gurney et al., 1994; Wong et al., 1995) .
The mechanisms by which SOD1 mutations cause ALS remain unclear, but accumulating data indicate a significant role for the biometals zinc (Zn) and copper (Cu) (Elliott, 2001) . ALS-causing mutations alter the metal binding capacity of SOD1 (Rodriguez et al., 2002; Hayward et al., 2002) and this can result in misfolding of the protein and its aggregation (Ding and Dokholyan, 2008; Bourassa et al., 2014) . Further to this, previous studies have suggested that Zn-deficient SOD1 is a significant toxic form of SOD1: Zn-deficient mutant SOD1 and Zn-deficient wild-type SOD1 are both toxic to motor neurons in culture due to their capacity to promote peroxynitrite mediated damage (Crow et al., 1997; Estevez, 1999) . It has also been shown that loss of Neurobiology of Disease 81 (2015) 20-24 Zn from SOD1 alters conformation of the homodimer, which results in the redox-active Cu II ion in the active site becoming more accessible to intracellular reductants leading to reduction to Cu I (Roberts et al., 2007) . Under these conditions Cu I promotes the formation of superoxide from molecular oxygen which is then able to react with nitric oxide to form peroxynitrite. Significantly, formation of a SOD1 heterodimer containing one Zn-deficient monomer and one fully metallated monomer stabilises the Zn-deficient form and increases its toxicity (Sahawneh et al., 2010) . Previous reports investigating the metallation status of different mutant forms of SOD1 concluded that incorrect metallation of mutant SOD1 is not involved in aggregation or toxicity due to the high levels of metal per dimer in the soluble form of the protein (Lelie et al., 2011) . However, the techniques used were not able to directly detect the metallation status of SOD1 and metallation status was inferred from the amount of metal per dimer. Recently developed techniques allow us to directly detect the metallation status of SOD1 allowing a more accurate investigation of the role of metals in SOD1 toxicity (Rhoads et al., 2011; Roberts et al., 2014) .
Treatment with the metal complex diacetyl-bis(4-methylthiosemicarbazonato)copper II [Cu II (atsm) ] is therapeutic in the SOD1G93A (Soon et al., 2011) and SOD1G37R (McAllum et al., 2013 ) mouse models of ALS. In the SOD1G37R mice there is a large pool of metal-deficient mutant SOD1 in the spinal cord tissue and the majority of this is due to Cu-deficient SOD1 (Roberts et al., 2014) . Treatment with Cu II (atsm) increases Cu in the spinal cord and decreases the Cu-deficient pool of SOD1 by delivering Cu to the mutant protein, indicating that Cudeficient SOD1 may play a role in ALS-like pathogenesis in these mice (Roberts et al., 2014) . Treatment with Cu II (atsm) also increased the Zn content of SOD1 and this was proposed to be due to stabilisation of the protein (Roberts et al., 2014) . However, given that treatment with Cu II (atsm) increased the Cu content and the Zn content of mutant SOD1 in the spinal cords of SOD1G37R mice (Roberts et al., 2014) , it remained unclear whether the strong therapeutic outcomes for the Cu II (atsm) treatment (McAllum et al., 2013) were due to its effects on the Cu-deficient or Zn-deficient SOD1. In an attempt to delineate the importance of Cu versus Zn delivery in the therapeutic activity of Cu II (atsm), mice in the present study were treated with the Cu II (atsm) analogue, Zn II (atsm). Locomotor function and survival of the mice were assessed to determine therapeutic effects and the metal content of spinal cord tissue from treated mice was analysed using hyphenated HPLC-ICP-MS.
Methods
Animals SOD1G37R mice purchased from the Jackson Laboratory were established and maintained as a colony by breeding with C57BL/6 non-transgenic mice. The genotype of these mice was determined using the REDExtract-N-Amp™ Tissue PCR kit (Sigma) to prepare DNA from tail snips taken from the mice at the age of weaning. Primers and cycle times used were those taken from the Jackson Laboratory website. Mice were housed in standard boxes with sawdust and shredded paper for bedding with 2-5 animals per box. All procedures were approved by an institutional animal ethics committee (University of Melbourne).
Preparation and administration of Zn

II (atsm)
Zn II (atsm) was prepared as previously described (Cowley et al., 2002 (Cowley et al., , 2005 . For administration to mice, Zn II (atsm) was prepared daily by suspending in standard suspension vehicle [SSV: 0.9% (w/v) NaCl, 0.5% (w/v) Na-carboxymethylcellulose (medium viscosity), 0.5% (w/v) benzyl alcohol and 0.4% (w/v) Tween-80] at a concentration of 7.5 mg mL −1
. Transgenic mice and non-transgenic littermates were treated daily by oral gavage with 30 mg kg −1 Zn II (atsm) or an equivalent volume of vehicle. Approximately equal numbers of male and female mice were included in each treatment group. Treatment of SOD1G37R mice with Zn II (atsm) was performed concurrently with treatments performed for one of our previous studies (McAllum et al., 2013) . Survival and rotarod data presented herein for vehicle-treated mice has been published previously (McAllum et al., 2013) and is reproduced with permission from the publisher Informa Healthcare. None of the biochemical analyses in the present study, including data from vehicle treated mice, has been published previously.
Assessment of locomotor function
The locomotor function of the mice was assessed twice a week beginning at 12 weeks of age using the rotarod task. The rotarod was set to accelerate from 4 to 40 rpm over 180 s. The time at which the mouse failed the task was recorded as latency to fall. During each testing session, every mouse was tested twice and the highest latency to fall score was recorded. Researchers administering the task were blind to the genotypes and treatments of the mice.
Determining disease end-stage
End-stage was defined as the age at which mice had a rotarod score of less than 3 s and were unable to right themselves in less than 30 s when place on their side due to hind limb paralysis. In accordance with ethical procedures, mice were killed at disease end-stage by cervical dislocation. Researchers determining end-stage were blind to treatment group.
Tissue collection and preparation for analysis
A cohort of treated mice was reserved for tissue collection at 24 weeks of age. Mice were anesthetised with ketamine (120 mg kg ) prepared in phosphate buffered saline (PBS). Once fully anesthetised the mice were perfused with PBS containing protease inhibitors, phosphatase inhibitor cocktail and heparin. Spinal cords were collected, frozen on dry ice immediately and then stored at −80°C until prepared for analysis. Prior to ICP-MS and LC-ICP-MS analyses, spinal cord tissue was prepared by homogenising in TBS containing protease inhibitors and soluble and insoluble material separated by centrifugation. Soluble material was used for both ICP-MS and LC-ICP-MS analyses and insoluble material was further processed according to published protocols (Maynard et al., 2006) before analysis by ICP-MS.
ICP-MS and LC-ICP-MS
Inductively coupled plasma mass spectrometry (ICP-MS) and hyphenated size exclusion chromatography, inductively coupled plasma mass spectrometry (LC-ICP-MS) were performed as previously described (Roberts et al., 2014; Maynard et al., 2006) with the following exceptions for LC-ICP-MS: a micro mist nebuliser was used instead of a Mira Mist; He gas flow was 3.3 mL min −1 ; spinal cord samples were homogenised in TBS containing protease inhibitors and 80 μg total protein was injected onto the column from the TBS soluble material. Elution of SOD1 from the column was determined using purified bovine SOD1 (Sigma Aldrich). Bovine SOD1 eluted at 399 s with a Ve/Vo of 1.5.
Transmetallation in CuCl 2
Zn II (atsm) solubilised in DMSO was mixed with increasing concentrations of CuCl 2 (CuCl 2 ·2H 2 O in DMSO) ranging from 0.2 to 1 Cu molar equivalents. After thorough mixing and 1 min incubation at ambient temperature, absorbance spectra from λ = 400-600 nm were measured using a UV/Vis spectrometer.
Statistics
All statistics were performed using GraphPad Prism software. Rotarod data were analysed using a two-way repeated measures ANOVA with Bonferroni post test and survival data were analysed using the Log-rank (Mantel-Cox) test, a commonly used nonparametric test for survival analysis which assumes proportional hazard. All other data sets were analysed using the unpaired t-test to compare the mean of datasets.
Results and discussion
Locomotive function of vehicle treated SOD1G37R mice began to decline at approximately 150 days of age (Fig. 1A) (Roberts et al., 2014) . A significant pool of Zn-deficient SOD1 also exists within the spinal cords of these mice but this is present at a lower concentration (~1.2 μM) than the Cu-deficient SOD1 (Roberts et al., 2014) . Given that this in vivo concentration of Zn-deficient SOD1 is higher than the concentration required to kill motor neurons in vitro (Crow et al., 1997) , it is possible that the relatively small pool of Zn-deficient SOD1 contributes to motor neuron death or dysfunction in vivo. We therefore assessed whether the therapeutic activity observed for Zn II (atsm) in the SOD1G37R mice involved modulation of the Zn-deficient pool of SOD1 (Fig. 1) wet weight in the insoluble material ( Fig. 2A) . This is reflected in the Cu content of the SOD1 in the spinal cord which increased from 0.16 ± 0.01 to 0.23 ± 0.02 μg g −1 tissue wet weight in the Zn II (atsm) treated mice (Fig. 2B) . Consequently, the Cu:Zn ratio for spinal cord SOD1 also increased from 0.43 ± 0.008 in the vehicle treated SOD1G37R mice to 0.54 ± 0.015 in the Zn II (atsm) treated mice (Fig. 2C ). The Cu:Zn ratio in the vehicle-treated mice is consistent with that reported by others employing a similar method (Lelie et al., 2011) . While this result was unexpected for mice treated with a Zn-compound, it lends support to the potential for Cu-deficient SOD1 to be a contributor to the ALS-like phenotype of mutant SOD1 mice and the therapeutic efficacy of increasing levels of bioavailable Cu in the spinal cord (Roberts et al., 2014) . Presuming that the ALS-like phenotype of the SOD1G37R mice is driven solely by the presence of mutant SOD1, Zn II (atsm) improves the locomotive function and survival of the mice by increasing the Cu content of the mutant SOD1 (Fig. 2) . The relative chemical properties of Zn Cu equivalents and readily transmetallate in the presence of available Cu (Barnard et al., 2008; Donnelly et al., 2008) which can influence the cellular activity of these compounds in vitro and in vivo (Donnelly et al., 2008; Petering, 1974) . If this occurs with Zn II (atsm) in the (atsm) or vehicle was assessed using the rotarod assay and recorded as latency to fall (n = 11 and 14 respectively; p b 0.0001). Due to mice reaching end-stage, the number of mice per treatment group begins to decline at 164 days for the vehicle-treated group and 201 days for the Zn II (atsm)-treated group. The dotted line indicates the age at which tissue was collected from a second cohort of mice for additional analyses in Fig. 2 . B. The locomotor function of non-transgenic C57BL/6 mice treated with Zn II (atsm) or vehicle was assessed using the rotarod assay and recorded as latency to fall (n = 16 and 21, respectively). C. KaplanMeier survival curves for the same mice used in Fig. 1A. (p b 0.0001) . Error bars in A and B represent SEM. Note, all data for vehicle treated mice have previously been published (McAllum et al., 2013) (Holland et al., 2007; Matsumoto et al., 1992; Saji et al., 1992) . Given this high susceptibility to transmetallation and the likelihood that orally administered Zn II (atsm) encounters available Cu (e.g. Cu from food in the digestive system), in vivo transmetallation of Zn II (atsm) appears to support the observed changes to total Cu ( Fig. 2A) (atsm) in the SOD1G37R mice is analogous to results from an earlier study which examined the closely related compounds 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone) (H 2 kts) and 3-ethoxy-2-oxobutyraldehyde bis(N 4 -dimethylthiosemicarbazone) (H 2 ktsm) and their respective Cu-and Zn-complexes (Petering, 1974) . When investigating the anti-cancer cytotoxic activity of these compounds, the metal-free ligands and their Cu and Zn complexes demonstrated clear cytotoxic activity, but metal-free ligands and Zn-complexes were only active when administered with a Cu supplement (Petering, 1974 (atsm) as demonstrated in a previous study (Roberts et al., 2014 ). This may be because rectifying potential Zn deficiencies in these mice has less of an impact on their phenotype than rectifying Cu deficiencies via strategies that increase Cu bio-availability (Roberts et al., 2014) (atsm) has confounded our attempt to investigate the potential to treat ALS-like symptoms in SOD1G37R mice by specifically delivering bio-available Zn. Compounds less amenable to transmetallation may be required to delineate these two metals in mutant SOD1 models of ALS, in both their role in pathogenesis and their opportunity for therapeutic intervention.
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